Therefore, information from both BM and PL would provide a more holistic picture of the tumour genome, with our data demonstrating that a proportion of prognostically significant TP53 mutations will likely have been undetected in prior whole exome sequencing/single-site BM biopsy studies. This evidence concerns the gene TP53 and neoplasm.